It should be noted that genetic disruption of both 12-LOX and 15-LOX in multiple diabetic models largely recapitulates the Aloxe3-mediated enhancement of hepatic insulin sensitivity and reduced hepatic steatosis (15–17). Here, ALOXE3 is linked to fatty liver disease.